大剂量氯沙坦降低肾小球性蛋白尿的临床观察  

Efficacy of Large dose of Losartan in Reducing Nephrotic Proteinuria

作　　者：熊重祥[1] 于钟[1] 邹和群[1] 赖德源[1] 姚娟 黄志清[1] 

机构地区：[1]中山医科大学孙逸仙纪念医院肾内科,广州510120

出　　处：《中国中西医结合肾病杂志》2002年第2期85-87,共3页Chinese Journal of Integrated Traditional and Western Nephrology

摘　　要：目的 :观察大剂量氯沙坦降低肾小球性蛋白尿的作用 ,探讨氯沙坦治疗蛋白尿的临床合理剂量及可能的作用机制。方法 :本临床观察采用开放实验自身对照的方法 ,对三组肾病性蛋白尿的患者分别服用常规剂量 (5 0mg/d) ,两倍剂量 (10 0mg/d) ,三倍剂量氯沙坦 (15 0mg/d) 8周的患者进行血Cr、BUN、UA及 2 4h尿蛋白定量检测。结果 :氯沙坦能有效降低肾小球性蛋白尿 ,三组治疗前后 2 4h尿蛋白定量均数比较及组间方差分析差异具有显著性。结论 :氯沙坦对肾小球疾病引起蛋白尿有治疗作用 ,在一定剂量范围内 。Objective: To study the efficacy and optimal dosage of losartan in reducing proteinuria. Methods: Open labeled self-control study was carried out. Serum creatinine, plasma urea and 24h-urinary protein excretion were measured in three groups of patients treated with losartan of routine dose(50 mg/d), double dose(100 mg/d)and triple dose(150 mg/d)for 8 weeks respectively. Results: Losartan redcuced glomerular proteinuria effectively. Urinary protein excretion was significantly reduced by losartan (P<0.05) and the decrease in proteinuria was associated with dosage of losartan. Conclusions: Reduction of proteinuria in glomerular diseases by losartan is associated with its dosage.

关 键 词：氯沙坦 肾小球性蛋白尿 肾脏保护 合理剂量 药理机制 

分 类 号：R692.05[医药卫生—泌尿科学]